Peculiarities of Bacteriophages Use in Clinical Practice

Peculiarities of Bacteriophages Use in Clinical Practice


  • Irma Korinteli Tbilisi State Medical University
  • Helen Phagava Tbilisi State Medical University
  • Karaman Pagava Tbilisi State Medical University



Infectious diseases are one of the most common causes of morbidity worldwide. Despite the scientific and technological advances of the 21st century, the mortality rate of infections remains high. Inappropriate use of antibiotics in recent years has particularly increased the number of antibiotic-resistant strains. Bacteriophage is a virus, which has an ability to destroy a bacterial cell, including antibiotic-resistant strains. Bacteriophage is considered as an alternative treatment for respiratory and gastrointestinal infections. Therefore, it will be very informative to identify the features of bacteriophage use in clinical practice. The aim was to study bacteriophage use in clinical practice in Georgia by various physicians. A questionnaire was used to assess the bacteriophage use. Overall 200 acting physicians were interviewed. 71.2% of respondents use phage in clinical practice. Most frequently are being used pyobacteriophage (43.1%) and intestiphage (32.3%) Most of them treat adults. However, as expected, phages are used more extensively in pediatrics. The phages are mainly used for treatment of respiratory and intestinal infections. Commonly doctors prescribe a phage whithout antibiotic which is a positive trend. 38.2% of physicians assessed the efficiency of the phage as 5 out of 5 (4.7% assessed it as 1 out of 5). It has been shown that in order to improve phagotherapy it is important to increase phage availability, reduce prices, develop national guidelines and provide more information about bacteriophages.


Download data is not yet available.


WHO-Global Health Observatory (GHO) data. 10 causes of death, Situation and trends

Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. /Versporten A et all/. The Lancet, Volume 6, Issue 6, e619-629, June 2018

Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials /Vandenheuvel D et all/.Annual Review of Virology, Volume 2, e599-618, Nov 2015

Some immunological changes in children with bacterial infections treated with bacteriophages /Pagava K. et all/.Georgian Medical News, 2012(212), e64-69, Nov 2012

What happens when the child gets bacteriophage per os? /Pagava K. et all/. Georgian Medical News, 2011(101-105), e196-197, Jul 2011

Per os given bacteriophages changes the clinical course of diseases caused by bacterial agents in children. /Pagava K. et all/.Georgian Medical News, 2012(211), e60-66, Oct 2012

Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections /Lehman SM et all /. Virusses 2019, Volume 11, No. 1, e88, Jun 2019

ფარმაცევტული საქმიანობის უწყობრივი რეესტრი, იმპორტ/ექსპორტის ანალიზი




How to Cite

Korinteli, I., Phagava, H., & Pagava, K. (2022). Peculiarities of Bacteriophages Use in Clinical Practice. Experimental and Clinical Medicine Georgia, 47–51.




Most read articles by the same author(s)

1 2 > >>